Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.55 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | F7 | P08709 | 1/20 | 0.51 |
| ▸ | F3 | P13726 | 1/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | EIF4A3 | P38919 | 2/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6517283 | 0.84 | HRH3 (0.59) | PIN1SMAD3TDP1HRH3KDM4E | |
| SCHEMBL3629675 | 0.83 | HRH3 (0.70) | HRH3KDM4EHPGDHSD17B10ALDH1A1 | |
| SCHEMBL3625932 | 0.81 | HRH3 (0.57) | PIN1SMAD3TDP1HRH3KDM4E | |
| SCHEMBL29415437 | 0.80 | SMAD3 (0.68) | PIN1SMAD3TDP1HRH3KDM4E | |
| SCHEMBL1842307 | 0.80 | SMAD3 (0.68) | PIN1SMAD3TDP1HRH3KDM4E | |
| SCHEMBL1734329 | 0.79 | PIN1 (0.65) | PIN1SMAD3TDP1HRH3KDM4E | |
| SCHEMBL3960955 | 0.77 | KDM4E (0.57) | PIN1SMAD3TDP1HRH3KDM4E | |
| SCHEMBL6513774 | 0.76 | PIN1 (0.61) | PIN1SMAD3TDP1HRH3KDM4E | |
| SCHEMBL24197050 | 0.75 | KDM4E (0.60) | TDP1KDM4EHPGDHSD17B10ALDH1A1 | |
| SCHEMBL30270496 | 0.75 | KDM4E (0.60) | TDP1KDM4EHPGDHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278089-B2 | Method of treating HCV infection with a small molecule CHK2 inhibitor | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-03-08 | — | — | US | disclosed |
| US-20140294767-A1 | METHOD OF TREATING HCV INFECTION WITH A SMALL MOLECULE CHK2 INHIBITOR | PROVID PHARMACEUTICALS, INC. | 2014-10-02 | — | — | US | disclosed |
| EP-2770993-A2 | METHOD OF TREATING HCV INFECTION WITH A SMALL MOLECULE CHK2 INHIBITOR | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8765802-B2 | Kinase inhibitors, compositions thereof, and methods of use therewith | PROVID PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2155675-B1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | PROVID PHARMACEUTICALS INC (US) | 2014-02-19 | — | — | EP | disclosed |
| WO-2013063462-A2 | METHOD OF TREATING HCV INFECTION WITH A SMALL MOLECULE CHK2 INHIBITOR | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-05-02 | — | — | WO | disclosed |
| EP-2155675-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | Provid Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090018141-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | PROVID PHARMACEUTICALS, INC. | 2009-01-15 | — | — | US | disclosed |
| WO-2008156573-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | PROVID PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294767-A1 | METHOD OF TREATING HCV INFECTION WITH A SMALL MOLECULE CHK2 INHIBITOR | CHEK2, CHEK1, CDK2 | PIN1 1170/4885SMAD3 2095/4885TDP1 1361/4885 |
| US-20090018141-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | CHEK2, ATM, CHEK1 | PIN1 2789/4885SMAD3 1685/4885TDP1 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.